A Study of NX-1607 in Adults With Advanced Malignancies
This research study is investigating a new medication, NX-1607, for adults who have advanced cancers like ovarian cancer, stomach cancer, head and neck cancer, melanoma, or lung cancer, among others. The main goals are to understand if NX-1607 is safe for patients and to see if it has any anti-cancer effects. In some parts of the study, NX-1607 might be given on its own, and in other parts, it might be combined with an existing chemotherapy drug called Paclitaxel. This is an early-stage study, meaning it's one of the first times this new treatment is being tested in people. It's for patients whose current treatments haven’t worked well, are no longer suitable, or where standard options don't exist.
At a glance
What is this study about?
This study is an early-stage clinical trial looking at a brand-new medicine called NX-1607. It's designed for adult patients who have various types of advanced cancer, such as some forms of ovarian, stomach, head and neck, or lung cancer, as well as melanoma and breast cancer. The main aim of this research is to see how safe this new drug is and whether it shows any signs of helping to fight these cancers. This is important because it could lead to new ways to treat conditions where current therapies aren't enough.
The study has two main parts. In the first part, called Phase 1a, doctors will give different doses of NX-1607 to patients to find the safest and most effective dose. Some patients will receive NX-1607 on its own, while others might receive it alongside another common cancer drug called Paclitaxel. This part of the study is for patients whose cancer has either not responded to standard treatments, or if standard treatments are not suitable or available for them. The second part, Phase 1b, will then use the best doses found in Phase 1a to further investigate how well NX-1607 works, either on its own or with Paclitaxel, in specific types of advanced cancer.
Taking part in a study like this means you would be helping doctors learn more about potential new treatments. It's important to remember that this is an early-stage trial, so while we hope for positive effects, the primary focus is on understanding the drug's safety and how the body reacts to it. The study will carefully monitor all participants for any side effects and to see if the treatment has any impact on their cancer.
Key takeaways
- This study is testing a new drug, NX-1607, for advanced cancers.
- It's an early-stage study focused on safety and early signs of effectiveness.
- Some patients will receive NX-1607 alone, others with Paclitaxel.
- It's for people whose cancers haven't responded to standard treatments or where options are limited.
- Regular health checks, blood tests, and scans will be part of the process.
- You can withdraw from the study at any time.
Who may be eligible?
To be considered for this study, you would generally need to be at least 18 years old and have a confirmed diagnosis of certain advanced cancers like ovarian, stomach, head and neck, melanoma, or lung cancer, among others. Your cancer must be measurable, meaning doctors can track its size. This study is typically for those whose cancer has spread or cannot be removed by surgery, and where standard treatments haven't worked, aren't suitable, or aren't available.
There are also some general health requirements. You should be in reasonably good health, with your body organs working well, and able to do most of your daily activities without much help (this is often called having a good 'performance status'). You must also have finished any previous cancer treatments a certain amount of time before starting this study. If you're a woman who could become pregnant, you would need to use effective birth control throughout the study.
However, some conditions would mean you couldn't take part. These include having active, untreated brain tumours, uncontrolled serious illnesses like high blood pressure or diabetes, or current active infections needing treatment. Your study doctor and the research team will carefully review all your medical information to determine if this study is right for you.
- Are you 18 years or older?
- Do you have a diagnosis of certain advanced cancers like ovarian, stomach, head and neck, lung, or breast cancer?
- Has your cancer spread, or is it unable to be removed by surgery?
- Have standard treatments for your cancer not worked, or are they not suitable for you?
- Are you generally well and able to carry out most daily activities?
- Do you not have any active, untreated brain tumours or uncontrolled serious illnesses?
This is a guide only — the research team will confirm whether you can take part.
What does participation involve?
If you join this study, you'll be given the new medication, NX-1607, probably by injection or infusion. You might also receive another chemotherapy drug called Paclitaxel, depending on the part of the study you are in. You'll have regular visits to the clinic for medical check-ups, blood tests, and scans to monitor your health and how the treatment is affecting your cancer. These visits will also be used to check for any side effects. You might also be asked to have a small tissue sample (biopsy) taken from your tumour, particularly in the later stages of the study. The exact number of visits and the total length of your participation will depend on how you respond to the treatment and what the study doctors determine is best for you, but generally, early-stage trials involve frequent monitoring and can last for several months or longer.
Potential risks and benefits
Locations (17)
- City of HopeDuarte, United States· Completed
- University of Southern CaliforniaLos Angeles, United States· Recruiting
- University of California, San FranciscoSan Francisco, United States· Recruiting
- University of Colorado School of MedicineAurora, United States· Recruiting
- University of ChicagoChicago, United States· Recruiting
- University of North CarolinaChapel Hill, United States· Recruiting
- University of OklahomaOklahoma City, United States· Recruiting
- MD Anderson Cancer CenterHouston, United States· Recruiting
- University of VirginiaCharlottesville, United States· Recruiting
- Fred Hutchinson Cancer CenterSeattle, United States· Recruiting
- Royal Marsden Hospital NHS Foundation TrustSutton, United Kingdom· Recruiting
- Addenbrookes Cambridge University HospitalCambridge, United Kingdom· Recruiting
+5 more sites — see the official record for the full list.
Common questions
What is NX-1607?
NX-1607 is a new experimental drug being studied as a potential treatment for various advanced cancers.
Will I get NX-1607 on its own or with another drug?
Depending on which part of the study you join, you might receive NX-1607 by itself or in combination with an existing chemotherapy drug called Paclitaxel.
What types of cancer is this study for?
This study is for adults with advanced forms of several cancers, including ovarian, stomach, head and neck, lung, melanoma, and breast cancer, among others.
Is this a new treatment?
Yes, this is an early-stage (Phase 1) study, meaning it's one of the first times this new drug, NX-1607, is being tested in people.
What happens if I want to stop participating?
You are free to leave the study at any time, for any reason, and it will not affect your ongoing medical care.
How to find out more
Nurix Therapeutics Patient Outreach
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.